menu
    • menu

    Company profile for OncoArendi Therapeutics

    NEW Drugs in Dev: 1
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At OncoArendi we search for innovative ways to help patients with incurable diseases. We are a biotech company discovering and developing new drugs up to clinical proof-of-concept`. We focus on small molecules and pursue innovative drug target platforms that have broad therapeutic potential. Our ambition is to discover, develop and commercialize breakthrough medicines in cancer, fibrotic and inflammatory diseases. We constantl...
    At OncoArendi we search for innovative ways to help patients with incurable diseases. We are a biotech company discovering and developing new drugs up to clinical proof-of-concept`. We focus on small molecules and pursue innovative drug target platforms that have broad therapeutic potential. Our ambition is to discover, develop and commercialize breakthrough medicines in cancer, fibrotic and inflammatory diseases. We constantly seek partnerships with academic, clinical and business partners. We play a leading role in shaping the Polish biotech industry by pioneering innovative drug discovery and providing career opportunities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncoArendi TherapeuticsPoland Flag
    Country
    Country
    Poland
    Address
    Address
    Żwirki i Wigury 101, 02-089 Warsaw
    Telephone
    Telephone
    +48 (22) 552 67 24
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncoarendi.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncoarendi-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/oncoarendi

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OncoArendi Tx Reports Continued Strategic and Operational Momentum for 12 Months
    OncoArendi Tx Reports Continued Strategic and Operational Momentum for 12 Months

    24 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/oncoarendi-therapeutics-reports-continued-strategic-and-operational-momentum-for-12-months-ended-31-december-2021-301510564.html

    PRNEWSWIRE
    24 Mar 2022
    Share Share
    OncoArendi Tx Announces License Option Agreement with University of Michigan
    OncoArendi Tx Announces License Option Agreement with University of Michigan

    11 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/oncoarendi-therapeutics-announces-a-license-option-agreement-with-university-of-michigan-301501034.html

    PRNEWSWIRE
    11 Mar 2022
    Share Share
    KriSan Biotech and OncoArendi Therapeutic (OAT) have entered into an agreement of API supply from Pre-IND to Phase 2.
    KriSan Biotech and OncoArendi Therapeutic (OAT) have entered into an agreement of API supply from Pre-IND to Phase 2.

    09 Sep 2019

    // PRESS RELEASE

    https://en.krisanbiotech.com/?page_id=49

    PRESS RELEASE
    09 Sep 2019
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search